Repaglinide

• Type 2 Diabetes
• Postprandial Hyperglycemia
• Glycemic Control

Repaglinide (brand name Prandin) is a short-acting oral insulin secretagogue from the meglitinide class, used to control postprandial hyperglycemia in adults with type 2 diabetes mellitus. Its rapid onset and short duration make it a useful tool when meal timing is irregular, when the priority is targeted control of post-meal glucose spikes, or when chronic kidney disease limits the use of metformin and other oral options.

Mechanism of Action

Repaglinide closes ATP-sensitive potassium channels on the pancreatic beta cell membrane by binding the SUR1 subunit at a site distinct from where sulfonylureas such as glipizide or glimepiride bind. Channel closure depolarizes the cell, opens voltage-gated calcium channels, and triggers exocytosis of pre-formed insulin granules. The result is a rapid burst of insulin release that begins within 15 to 30 minutes of dosing and dissipates over three to four hours, mimicking the first-phase insulin response that is characteristically blunted in type 2 diabetes.

Because release is glucose-dependent in vivo (the depolarization effect is amplified by the rising glucose load of a meal) and the drug is rapidly cleared by hepatic CYP2C8 and CYP3A4 metabolism, the risk of prolonged hypoglycemia is generally lower than with longer-acting sulfonylureas — though it is by no means absent, particularly in older patients or those with renal or hepatic impairment. The half-life is approximately one hour, and clearance is almost entirely biliary, with negligible renal elimination of unchanged drug.

Clinical Use

Repaglinide is not first-line therapy for type 2 diabetes — that role belongs to metformin, with subsequent layering of GLP-1 receptor agonists like semaglutide or liraglutide, or SGLT2 inhibitors like empagliflozin and dapagliflozin for patients with cardiovascular or renal indications. The American Diabetes Association's Standards of Care summarize this stepwise approach, which now emphasizes cardiorenal benefit as much as glucose lowering in agent selection.

Repaglinide finds a niche in several specific situations. Patients with significant chronic kidney disease can use it where many oral options are contraindicated or require dose reduction, since renal clearance contributes minimally to its elimination. Patients with markedly variable meal patterns — shift workers, those with poor appetite from chemotherapy or chronic illness — would be at risk of hypoglycemia from a long-acting sulfonylurea between meals; the meal-by-meal nature of repaglinide dosing matches their reality better. Patients with sulfa allergy concerns who cannot take sulfonylureas have an alternative secretagogue available.

Its competitor nateglinide is similar in mechanism but generally less potent and used somewhat less. When postprandial control remains inadequate despite oral therapy, basal-bolus insulin with insulin glargine and insulin lispro typically replaces meglitinides, since insulin offers more granular control and titratable dosing. Patients with impaired fasting glucose without overt diabetes are not candidates — repaglinide is approved only for established type 2 diabetes.

How to Take It

Repaglinide is taken within 15 minutes before each main meal, following a 'no meal, no dose; extra meal, extra dose' rule that distinguishes it from most oral diabetes medications. Starting doses are typically 0.5 mg before each meal in patients with mild hyperglycemia or those switching from another oral agent, or 1 to 2 mg in those with higher A1c values at baseline. The dose can be doubled weekly to a maximum of 4 mg per meal and 16 mg per day, with adjustment guided by self-monitored postprandial glucose readings.

Tablets are kept at room temperature in their original container. Patients should always carry a fast-acting carbohydrate source for hypoglycemia — glucose tablets, juice boxes, or hard candy — and family members should be aware of hypoglycemia symptoms and treatment. Our eating out with diabetes article offers practical advice on dose timing in restaurant settings, where meal arrival times are unpredictable. The general principle is to wait until food is in front of you before dosing, particularly in unfamiliar settings.

The MedlinePlus repaglinide page is a useful patient resource. Alcohol intake should be moderated and never undertaken on an empty stomach because of the additive hypoglycemia risk.

Monitoring and Follow-Up

A1c is checked every three months until at goal, then every six months — see understanding A1c diabetes for an explanation of the test and its limits. Self-monitored or continuous glucose monitoring data, particularly two-hour postprandial values, guide individual dose adjustments meal by meal. Periodic renal function, lipid panel, and liver enzymes are part of routine diabetes care; see understanding blood work lab panels for context on these laboratory values.

For patients with prediabetes or borderline A1c values being considered for therapy, the prediabetes reversal guide covers lifestyle approaches that should accompany — and sometimes replace — pharmacotherapy. Annual urine albumin-to-creatinine ratio, dilated eye exam, and foot exam complete the routine diabetes monitoring picture. The FDA prescribing information for repaglinide is available through accessdata.fda.gov.

Special Populations

Repaglinide is contraindicated with gemfibrozil, which raises repaglinide AUC roughly eightfold via CYP2C8 inhibition and produces severe, prolonged hypoglycemia that has resulted in deaths. Caution is required with clopidogrel, trimethoprim, and clarithromycin for similar reasons; rifampin and phenytoin reduce levels markedly and may require dose increase or use of an alternative agent.

The drug is preferred over many alternatives in moderate-to-severe renal impairment because it is not renally cleared, but starting at 0.5 mg with cautious titration is wise, since insulin clearance and overall hypoglycemia risk increase with kidney disease. Hepatic impairment prolongs exposure; longer dosing intervals or lower doses may be appropriate. Repaglinide is not recommended in pregnancy — insulin is preferred — and is not approved for pediatric use. Beta-blockers may mask the adrenergic warning signs of hypoglycemia (tremor, palpitations) but not sweating. Older adults are at increased risk of hypoglycemia and may benefit from lower starting doses and more cautious titration.

Lifestyle and Supportive Care

Medication is one element of type 2 diabetes care; lifestyle remains foundational regardless of which oral or injectable agents are used. A dietary pattern emphasizing non-starchy vegetables, lean proteins, whole grains, legumes, nuts, and healthy fats — broadly aligned with Mediterranean or DASH eating patterns — improves glycemic control, blood pressure, and cardiovascular risk. Limiting refined carbohydrates and added sugars reduces the postprandial spikes that repaglinide is meant to address. Small, frequent meals of consistent carbohydrate content match the rapid on-off action of meglitinides better than three large meals.

Weight loss of even 5 to 10 percent of body weight produces meaningful improvements in A1c and may allow dose reduction of diabetes medications. Aerobic exercise (at least 150 minutes per week of moderate intensity) and resistance training (two to three sessions per week) both improve insulin sensitivity and glucose disposal. Patients should check glucose before exercise, carry a fast-acting carbohydrate source, and time exercise to avoid dose peaks if hypoglycemia has been an issue.

Smoking cessation, blood pressure control, statin therapy where indicated, and annual screening for diabetes complications (eye exam, foot exam, urine albumin, lipid panel) round out comprehensive care. Foot care is particularly important — daily inspection for wounds, well-fitting footwear, and prompt attention to any sore — given the prevalence of diabetic neuropathy and the consequences of foot ulcers in this population. Sleep apnea is common and undiagnosed in many patients with type 2 diabetes; screening is reasonable, since treatment improves both glycemic control and cardiovascular risk. Patients should also be aware that significant alcohol intake can produce delayed hypoglycemia, sometimes hours after the drink and after the next dose of repaglinide.

When to Contact Your Doctor

Recurrent or unexplained hypoglycemia, particularly if it requires assistance from another person, is a warning sign that requires regimen review. Unexplained weight loss, persistent nausea or right upper quadrant pain, jaundice, or progressive fatigue should be reported. Severe hypoglycemia with confusion, seizure, or loss of consciousness is a medical emergency requiring 911 and intramuscular glucagon if available.

If you have questions about repaglinide or your overall diabetes treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.